A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older

NCT01646398 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

764

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Vaccines
Pneumococcal Conjugate Vaccine

Interventions

BIOLOGICAL: 13-valent pneumococcal conjugate vaccine
BIOLOGICAL: 23-valent pneumococcal polysaccharide vaccine

Sponsor

Pfizer